Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2026)

Indivior Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at -$144.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 49.47% year-over-year to -$144.0 million in Q1 2026; TTM through Mar 2026 was -$144.0 million, a 49.47% increase from a year earlier, with the FY2025 full-year figure at -$98.0 million, up 70.92% from the prior year.
• Common Equity eased to -$144.0 million in Q1 2026 per INDV's latest filing, from -$98.0 million in the prior quarter.
• Across five years, Common Equity topped out at -$15.0 million in Q4 2022 and bottomed at -$337.0 million in Q4 2024.
• The 5-year median for Common Equity is -$207.0 million (2025), against an average of -$207.2 million.
• Across the five-year window, Common Equity slumped 1126.67% in 2023 and jumped 70.92% in 2025, its largest moves.
• Year by year, Common Equity stood at -$15.0 million in 2022, then slumped by 1126.67% to -$184.0 million in 2023, then sank by 83.15% to -$337.0 million in 2024, then soared by 70.92% to -$98.0 million in 2025, then plunged by 46.94% to -$144.0 million in 2026.
• Per Business Quant, the three latest INDV Common Equity figures stand at -$144.0 million (Q1 2026), -$98.0 million (Q4 2025), and -$207.0 million (Q3 2025).